Table 1.
Summary of mouse immunogenicity studies with different EV71 vaccine candidates.
| EV71 vaccine candidates | Adjuvant formulated | Total IgG titers | Western blot | Virus neutralization titer | ||||
|---|---|---|---|---|---|---|---|---|
| VP1-43 | VP2-28 | rVP1 | rVP2 | rVP3 | EV71 (B4 E59) | CVA16 (N5079) | ||
| VP1-43 | Alum | 1/3200 | ++ | <1/8 | <1/8 | |||
| VP1-43 | CFA/IFA | 1/6400 | +++ | 1/32 | <1/8 | |||
| VP2-28 | Alum | 1/200 | − | <1/8 | <1/8 | |||
| VP2-28 | CFA/IFA | 1/1600 | + | <1/8 | <1/8 | |||
| VP1-43/VP2-28 | CFA/IFA | 1/6400 | 1/800 | +++ | + | 1/32 | <1/8 | |
|
| ||||||||
| rVP1 | Alum | 1/6400 | +++ | <1/8 | <1/8 | |||
| rVP1 | CFA/IFA | 1/12800 | +++ | 1/128 | <1/8 | |||
| rVP2 | Alum | <1/100 | +++ | <1/8 | <1/8 | |||
| rVP2 | CFA/IFA | 1/200 | +++ | 1/8 | <1/8 | |||
| rVP3 | Alum | ++ | <1/8 | <1/8 | ||||
| rVP3 | CFA/IFA | +++ | 1/8 | <1/8 | ||||
|
| ||||||||
| EV71-VLP | PBS | 1/1600 | <1/100 | ++ | ++ | ++ | 1/64 | <1/8 |
| EV71-VLP | Alum | 1/6400 | <1/100 | ++ | ++ | ++ | 1/128 | <1/8 |
| EV71-VLP | CFA/IFA | 1/12800 | <1/100 | +++ | +++ | ++ | 1/160 | <1/8 |
|
| ||||||||
| 2 μg of inactivated | ||||||||
| EV71 virion | PBS | 1/6400 | <1/100 | +++ | +++ | ++ | 1/64 | <1/8 |
| EV71 virion | Alum | 1/12800 | <1/100 | +++ | +++ | ++ | 1/640 | <1/8 |
|
| ||||||||
| 5 μg of inactivated | ||||||||
| EV71 virion | Alum | 1/12800 | <1/100 | +++ | +++ | +++ | 1/2560 | <1/8 |
Three to six mice per group were immunized 3 times with EV71 vaccine candidates formulated with alum or CFA/IFA. Fifty micrograms of synthetic peptides, 20 μg of recombinant EV71 viral structural proteins, and 5 μg of recombinant virus-like particles (EV71-VLP) were used in the mouse immunogenicity studies. The protocols for IgG titer determination, western blot analysis, and virus neutralization assay are described in Section 2.